Citation Impact
Citing Papers
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation
2013
Role of nitric oxide in inflammatory diseases
2007 Standout
Regulation of hepatic stellate cells by connective tissue growth factor
2012
Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis
2008
Sepsis biomarkers: a review
2010 Standout
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin
2020 StandoutNobel
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
2008
TGF-β signaling in fibrosis
2011 Standout
Mechanisms of hepatic stellate cell activation
2017 Standout
Diagnosis and treatment of acute renal failure in patients with cirrhosis
2007
Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?
2003
Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury
2008
Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus
2010
Vascular disorders of the liver # †
2008 Standout
Nociceptin and urotensin-II concentrations in critically ill patients with sepsis
2008
Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
2013
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Acute renal failure in patients with cirrhosis: Perspectives in the age of MELD
2003
The role of nitric oxide
2006
The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat
2004
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
2007
Portal hypertensive bleeding in cirrhosis
2016 Standout
Graves' Ophthalmopathy
2010 Standout
Intrinsic Immunity Shapes Viral Resistance of Stem Cells
2017 StandoutNobel
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation
2008
Management of Varices and Variceal Hemorrhage in Cirrhosis
2010
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
2007
EMT: 2016
2016 Standout
TGF-β and fibrosis in different organs — molecular pathway imprints
2009 Standout
Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C
2007
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
2006
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
2013 Standout
The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste
2004 Standout
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
2014 Standout
Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes
2009 StandoutNobel
Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways
2015
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Vascular mediators in the injured liver
2003
Natural compounds for cancer treatment and prevention
2009 Standout
Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony
2019 Standout
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Rapamycin Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
2009
mTORC1 phosphorylates LARP6 to stimulate type I collagen expression
2017
Extrahepatic Platelet-Derived Growth Factor-β, Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice
2014
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Nucleotide‐binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis†
2009
Is urotensin‐II the new endothelin?
2002
Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
2007
Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway
2014
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis
2021
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis
2021
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
2011
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
HEPATIC FIBROSIS: Molecular Mechanisms and Drug Targets
2004
Works of Markus Neef being referenced
Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension
2002
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension
2001
Portal hypertension is associated with increased mRNA levels of vasopressor G‐protein‐coupled receptors in human hepatic arteries
2003
Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying Mechanisms
2005
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
2006
Elevated Soluble Tumor Necrosis Factor Receptor 75 Concentrations Identify Patients With Liver Cirrhosis at Risk of Death
2008
Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock‐out mice and is elevated in murine and human cirrhosis
2004
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
2005
Increased urotensin II plasma levels in patients with cirrhosis
2001